相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 1 Pharmacokinetic and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid Tumors
Faye M. Johnson et al.
CANCER (2010)
Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile
Xiaohai Li et al.
DRUG METABOLISM AND DISPOSITION (2010)
Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man With Lung Cancer
Marco Pellegrinotti et al.
ANNALS OF PHARMACOTHERAPY (2009)
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
R. Kumar et al.
BRITISH JOURNAL OF CANCER (2009)
Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects
Deborah A. Smith et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
Joshua Oe Haznedar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities
Xiaohai Li et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters
Shuiying Hu et al.
CLINICAL CANCER RESEARCH (2009)
Effects of Hepatic Impairment on the Pharmacokinetics of Nilotinib: An Open-Label, Single-Dose, Parallel-Group Study
Ophelia Q. P. Yin et al.
CLINICAL THERAPEUTICS (2009)
Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase, Accelerated Phase, or Blast Crisis: A Single- and Multiple-Dose, Open-Label Pharmacokinetic Study in Chinese Patients
Li Zhou et al.
CLINICAL THERAPEUTICS (2009)
Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways
Xiaohai Li et al.
DRUG METABOLISM AND DISPOSITION (2009)
Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene
Toshirou Nishida et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Erlotinib-induced dermatologic side-effects
H. Jorn Bovenschen et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2009)
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia
Dong-Wook Kim et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
A. Davies et al.
LEUKEMIA (2009)
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers
Jana Rolff et al.
JOURNAL OF ONCOLOGY (2009)
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
A. A. M. van der Veldt et al.
BRITISH JOURNAL OF CANCER (2008)
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
Chun-ling Dai et al.
CANCER RESEARCH (2008)
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications
Devendra K. Hiwase et al.
CLINICAL CANCER RESEARCH (2008)
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer
Quincy S. C. Chu et al.
CLINICAL CANCER RESEARCH (2008)
Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2008)
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva (R))
J. Luebbe et al.
DERMATOLOGY (2008)
Identification of the human enzymes involved in the oxidative metabolism of dasatinib: An effective approach for determining metabolite formation kinetics
Lifei Wang et al.
DRUG METABOLISM AND DISPOSITION (2008)
Lacteal Secretion, Fetal and Maternal Tissue Distribution of Dasatinib in Rats
Kan He et al.
DRUG METABOLISM AND DISPOSITION (2008)
Metabolism and disposition of dasatinib after oral administration to humans
Lisa J. Christopher et al.
DRUG METABOLISM AND DISPOSITION (2008)
Evaluation of [F-18]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
Helen Su et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Recurrent gefitinib-induced interstitial lung disease
Masaru Suzuki et al.
INTERNAL MEDICINE (2008)
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain
Brunilde Gril et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice
Serena Marchetti et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) disposition and drug interactions
Joseph W. Polli et al.
DRUG METABOLISM AND DISPOSITION (2008)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
Carolyn D. Britten et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib
Nielka R. van Erp et al.
CLINICAL CANCER RESEARCH (2007)
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Deborah L. White et al.
BLOOD (2007)
The value of label recommendations: How to dose lapatinib
Kevin M. Koch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sunitinib efficacy against advanced renal cell carcinoma
Robert J. Motzer et al.
JOURNAL OF UROLOGY (2007)
Pulmonary toxicity associated with erlotinib
Vincent Liu et al.
CHEST (2007)
Pharmacokinetics of gefitinib in humans:: The influence of gastrointestinal factors
Ebba Bergman et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2007)
Fulminant hepatic failure secondary to erlotinib
Weitian Liu et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
Bret Wacker et al.
CLINICAL CANCER RESEARCH (2007)
A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers
E. E. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
Jing Li et al.
CLINICAL CANCER RESEARCH (2007)
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial
Hagop Kantarjian et al.
BLOOD (2007)
Toxicological significance of mechanism-based inactivation of cytochrome P450 enzymes by drugs
Yasuhiro Masubuchi et al.
CRITICAL REVIEWS IN TOXICOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec)
Kun-Eek Kil et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN 107) therapy failure
Alfonso Quintas-Cardama et al.
BLOOD (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Liver toxicity after treatment with gefitinib and anastrozole: Drug-drug interactions through cytochrome p450?
Paolo Carlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Managing dermatologic toxicities of epidermal growth factor receptor inhibitors
Lillian S. Chou et al.
CLINICAL LUNG CANCER (2006)
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer
Seiji Nagashima et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements
Andrew Owen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
Deborah L. White et al.
BLOOD (2006)
Activation of T cells by carbamazepine and carbamazepine metabolites
Ying Wu et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
C Lathia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo
Markos Leggas et al.
CANCER RESEARCH (2006)
Effects of smoking on the pharmacokinetics of erlotinib
M Hamilton et al.
CLINICAL CANCER RESEARCH (2006)
Gefitinib-induced interstitial lung disease showing improvement after cessation: Disassociation of serum markers
H Kitajima et al.
RESPIROLOGY (2006)
A review of erlotinib and its clinical use
PA Tang et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer
AZ Dudek et al.
LUNG CANCER (2006)
Severe cutaneous toxicity following treatment with gefitinib (ZD1839)
JC Pascual et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Breast cancer metastasis to the central nervous system
RJ Weil et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva®) and gefitinib (Iressa®)
WS Siegel-Lakhai et al.
ONCOLOGIST (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
M Golemovic et al.
CLINICAL CANCER RESEARCH (2005)
Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies
C Gambacorti-Passerini et al.
LEUKEMIA (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients
P Breedveld et al.
CANCER RESEARCH (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Cytochrome P450-dependent metabolism of gefitinib
D McKillop et al.
XENOBIOTICA (2005)
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
HC Swaisland et al.
CLINICAL PHARMACOKINETICS (2005)
Single-dose clinical pharmacokinetic studies of gefitinib
HC Swaisland et al.
CLINICAL PHARMACOKINETICS (2005)
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
AE Bolton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion
B Peng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
C Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes
A Parkinson et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2004)
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
T Takano et al.
LUNG CANCER (2004)
In vitro metabolism of gefitinib in human liver microsomes
D Mckillop et al.
XENOBIOTICA (2004)
Acute lung injury as an adverse event of gefitinib
SI Inomata et al.
ANTI-CANCER DRUGS (2004)
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man
D McKillop et al.
XENOBIOTICA (2004)
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia
SG O'Brien et al.
BRITISH JOURNAL OF CANCER (2003)
Akt signaling regulates side population cell phenotype via Bcrp1 translocation
M Mogi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Acute lung injury as a possible adverse drug reaction related to gefitinib
R Ieki et al.
EUROPEAN RESPIRATORY JOURNAL (2003)
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors
K Nakagawa et al.
ANNALS OF ONCOLOGY (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Severe acute interstitial pneumonia and gefitinib
A Inoue et al.
LANCET (2003)
FDA drug approval summary: Gefitinib (ZD1839) (Iressa (R)) tablets
MH Cohen et al.
ONCOLOGIST (2003)
Imatinib: a selective tyrosine kinase inhibitor
PW Manley et al.
EUROPEAN JOURNAL OF CANCER (2002)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
M Ronson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
